Investigational drug · Phase 3
JX10
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Ischemic Stroke.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "JX10"
First trial start
2025
May 15, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JX10", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Ischemic Stroke
Approved drugs for the same conditions: Stroke prevention · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "JX10" as an intervention, largest first.
- Optimizing Reperfusion to Improve Outcomes and Neurologic FunctionPivotal-lookingRecruiting
Corxel PharmaceuticalsIndustry
NCT06990867 · 740 participants (planned) · Start May 15, 2025 · Primary completion Oct 31, 2029
Drug: JX10; Placebo · For: Acute Ischemic Stroke
Sites: Long Beach, California; Los Angeles, California; Sacramento, California · 104 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- [Novel Drugs and Therapeutic Strategies for Acute Ischemic Stroke:Focus on Tenecteplase].
Arakaki Y, Toyoda K · No Shinkei Geka 2026
- Intravenous thrombolysis for acute ischemic stroke in the extended time window of 4.5-24 h: a systematic review and network meta-analysis of randomized controlled trials.
Yu X, Sun X, Yang F · Front Neurol 2026
- Novel thrombolytic agents for acute ischemic stroke: A comprehensive review of current evidence.
Hotz JF, Kaindl L, Krebs S, et al. · J Neurol Sci 2025
- Discovery of Non-antibacterial Enrofloxacin Derivatives with Emerging Antiaging Effects through Drug Repurposing and Secondary Development.
Qiao S, Chen X, Chen Y, et al. · J Med Chem 2025
- Anti-Inflammatory Thrombolytic JX10 (TMS-007) in Late Presentation of Acute Ischemic Stroke.
Niizuma K, Nishimura N, Hasegawa K, et al. · Stroke 2024
- Genome-Wide Association Mapping of Yield and Grain Quality Traits in Winter Wheat Genotypes.
Tadesse W, Ogbonnaya FC, Jighly A, et al. · PLoS One 2015
Also in development for Acute Ischemic Stroke
- TAK-755rADAMTS13, recombinant ADAMTS13Phase 33 trials
Takeda · Thrombotic Thrombocytopenic Purpura (TTP), Acute Ischemic Stroke
- SovateltideIRL-1620, PMZ-1620Phase 32 trials
Pharmazz, Inc. · Traumatic Brain Injury, Acute Ischemic Stroke, Cerebral Stroke
- SHPL-49Phase 31 trial
Shanghai Hutchison Pharmaceuticals Limited · Acute Ischemic Stroke
- LT3001Phase 23 trials
Lumosa Therapeutics Co., Ltd. · Acute Ischemic Stroke
- LT3001 DrugPhase 22 trials
Shanghai Pharmaceuticals Holding Co., Ltd · Acute Ischemic Stroke
- B2065Phase 21 trial
Tasly Pharmaceutical Group Co., Ltd · Acute Ischemic Stroke
- BB-031DTRI-031Phase 21 trial
Basking Biosciences, Inc. · Acute Ischemic Stroke
- HRS-4029Phase 21 trial
Beijing Suncadia Pharmaceuticals Co., Ltd · Acute Ischemic Stroke
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.